Pharma has spent fifty years building formulation science around exactly that gap, and a growing number of nutraceutical ingredients, from curcumin to coenzyme Q10, sit in the same spot poorly soluble drugs did before that science existed
Poor absorption is a problem the pharmaceutical industry solved decades before most supplement formulators had to think about it. Compounds that show real biological activity in a lab often perform far worse once they're inside the body, because getting a molecule to dissolve, cross the gut wall and reach circulation is a separate engineering problem from proving the molecule does something useful. Pharma has spent fifty years building formulation science around exactly that gap, and a growing number of nutraceutical ingredients, from curcumin to coenzyme Q10, sit in the same spot poorly soluble drugs did before that science existed.
Some of that formulation science transfers to supplements directly, and some of it doesn't, because the ingredients, the regulations and the economics driving each industry differ in ways that matter for how a formula actually gets built. Knowing which techniques hold up under food-grade constraints, and knowing who on a team actually understands the difference, saves a formulation program from either overpromising on absorption or ignoring a fix that would meaningfully change how a product performs.
Compounds that show real biological activity in a lab often perform far worse once they're inside the body
Why so many popular actives barely get absorbed
Curcumin, resveratrol, quercetin and coenzyme Q10 share a chemical trait that has nothing to do with their reputations as beneficial compounds. They're poorly soluble in water, which means a large share of an accurately dosed capsule can pass through the gut without ever dissolving enough to cross into the bloodstream. Pharmaceutical scientists sort compounds by exactly this property, using a framework called the Biopharmaceutics Classification System, and drugs that land in the low-solubility categories face the same absorption ceiling regardless of how much active ingredient sits on the label.
That distinction explains why two products with identical curcumin content on the label can produce very different blood concentrations after someone takes them. The raw compound's solubility, not the dose, sets the upper limit on how much ever gets absorbed, and formulators who ignore that ceiling end up with a product that performs on paper but underdelivers in practice.
Where the expertise actually sits
Fixing that ceiling takes more than access to the right equipment, since most contract manufacturers already own the same homogenizers and spray dryers regardless of who's placing the order. It takes someone who understands dosage-form design and biopharmaceutics well enough to know which parts of a pharmaceutical technique are load-bearing and which parts exist only because a drug-grade excipient happened to be available. Food science programs rarely teach that material in depth, since biopharmaceutics and dosage-form design sit inside pharmacy curricula rather than nutrition or food technology degrees.
That's part of why supplement companies building out serious delivery science increasingly recruit people with a pharmacy background rather than a purely food science one. A doctor of pharmacy online degree still covers the same core pharmaceutics and biopharmaceutics coursework a campus program requires, and graduates already move into pharmaceutical research roles alongside more traditional clinical practice, which makes that training base a natural fit for a formulation team trying to build real absorption science rather than borrow a technique it doesn't fully understand.
It takes someone who understands dosage-form design and biopharmaceutics well enough to know which parts of a pharmaceutical technique are load-bearing and which parts exist only because a drug-grade excipient happened to be available
The solubility playbook pharma already wrote
Pharmaceutical formulators ran into this exact ceiling with a large share of new drug candidates, and the industry responded with several reliable fixes that trade coverage of pharmaceutical solubility work still groups into a short list of established approaches:
- Micronization, which reduces particle size to increase surface area and speed up dissolution
- Lipid-based and self-emulsifying delivery systems, which dissolve the compound in an oil and surfactant blend that disperses into fine droplets once it hits gastric fluid
- Amorphous solid dispersion, which locks the compound into a polymer matrix that dissolves faster than its crystalline form
- Cyclodextrin complexation, which tucks the compound inside a ring-shaped sugar molecule that is itself water soluble
Several of these already crossed over. Liposomal vitamin C and liposomal glutathione are common on supplement shelves for the same reason liposomal delivery shows up in pharma, because encapsulating a compound in a lipid layer can improve both stability and uptake.
Why the regulatory math doesn't match
Pharmaceutical companies can justify years of formulation work on a single molecule because a new drug application requires clinical proof of safety and efficacy before the product ever reaches a pharmacy shelf, and patent protection lets the company recover that investment through pricing. Dietary supplements don't follow that path. Ingredients reach the market under a much lighter framework built around generally recognized as safe status or new dietary ingredient notification, neither of which requires proof that the product works before it's sold.
That difference changes which techniques make financial sense. The polymer used in an amorphous solid dispersion for a prescription drug went through its own safety review as part of the drug's approval, but a nutraceutical formulator can't borrow that same polymer without separately establishing that it's food grade, since supplement manufacturers largely self-affirm ingredient safety rather than submitting to a premarket review at all. A national survey found that about half of Americans overestimate the FDA's oversight of supplements, assuming the agency either requires proof of safety or tests products directly, when neither is required under the GRAS or new dietary ingredient framework. Formulators end up rebuilding a version of the pharma solution from food-grade materials rather than adopting it outright.
Solid dispersion and cyclodextrin complexation can still work, but they usually need a food-grade polymer or cyclodextrin grade substituted in
Building a formulation program that doesn't overreach
Start with the techniques that already have food-grade precedent, since lipid-based and self-emulsifying systems use oils and surfactants that food regulators have already reviewed, which shortens the path to a workable formula considerably compared with a technique that requires a new excipient safety case from scratch. Solid dispersion and cyclodextrin complexation can still work, but they usually need a food-grade polymer or cyclodextrin grade substituted in, and that substitution has to be tested rather than assumed to behave the same way.
Whatever technique gets chosen, the only way to know it actually improved absorption is a real pharmacokinetic comparison against the unmodified ingredient, not a dissolution test run in a beaker. Dissolution data can show that a compound comes out of a capsule faster, but it can't show how much of that compound actually reaches circulation once digestion, gut transit and metabolism get involved. A formulation program built on borrowed pharmaceutical science only holds up if it borrows the standard for proof along with the technique.
